Please join the Pharming-sponsored symposium:

Are prodromes an early phase of HAE attacks? Defining the role of early symptoms in the acute treatment of HAE

Date: 4th May 2023
Time: 16:00 – 17:00 CET
Location: Ensana Thermal Hotel Margitsziget
H-1007 Budapest, Margitsziget,
Jázmin I-II room

This Pharming-sponsored pre-workshop symposium will be taking place before the opening session of the:

13th C1-inhibitor Deficiency & Angioedema Workshop, Budapest, Hungary

Acute treatment still retains a very important place in therapy for hereditary angioedema (HAE). Early signs and symptoms of an HAE attack may be helpful in supporting patient management.

Faculty

Prof Henriette Farkas
Semmelweis University, Budapest, Hungary

Prof Marc Riedl
University of California San Diego, US

Dr Mar Guilarte
University Hospital Vall d'Hebron, Barcelona, Spain

Agenda

16:00 – 16:05	**Introduction from Chair** Prof Henriette Farkas
16:05 – 16:20	**The role of acute treatment in HAE** Prof Marc Riedl, US
16:20 – 16:35	**What do we mean by 'early treatment' and how do we communicate effectively to our patients?** Prof Henriette Farkas
16:35 – 16:50	**Pharming prodromes research project** Dr Mar Guilarte
16:50 – 17:00	**Discussion and questions, summary and close** Led by Prof Farkas

Pharming®

Prescribing Information

RUCONEST® 2100 Units powder and solvent for solution for injection. **Active ingredient:** conestat alfa. **Composition:** One vial contains 2100 Units of conestat alfa, corresponding to 2100 U/14 ml after reconstitution, or a concentration of 150 U/ml. **Excipients:** Sucrose, sodium citrate (E331), citric acid. **Shelf life:** 4 years. **Storage conditions:** Do not store above 25°C. Store in the original package in order to protect from light. **Indication:** RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. **Contraindications:** Known or suspected allergy to rabbits. Hypersensitivity to the active substance or to any of the excipients. **Pregnancy and breast-feeding:** There is no experience with the use of RUCONEST® in pregnant and breast-feeding women. RUCONEST® is not recommended for use during pregnancy or breast-feeding, unless the treating physician judges the benefits to outweigh the possible risks. **Side effects:** Common: Nausea. Uncommon: Abdominal pain, diarrhea, sensation of tingling, prickling or numbness in the mouth, headache, dizziness, reduced sense of touch or sensation in skin or limbs, throat irritation, hives, swelling of the ears or the area around the ears. **Warning:** RUCONEST® contains sodium. RUCONEST® will be prescribed by a doctor. **Marketing Authorisation Holder:** Pharming Group N.V., Darwinweg 24, 2333 CR Leiden, the Netherlands. www.pharming.com. Last revised: April 2020. Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/ruconest-epar-product-information_en.pdf

Adverse events should be reported to Pharming Pharmacovigilance at safety@pharming.com.

Pharming®